Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Ovarian Neoplasms 46Lung Neoplasms 26Breast Neoplasms 26Fallopian Tube Neoplasms 23Small Cell Lung Carcinoma 18Carcinoma, Ovarian Epithelial 16Squamous Cell Carcinoma of Head and Neck 14Neoplasms 14Glioblastoma 13Triple Negative Breast Neoplasms 12Recurrence 11Head and Neck Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Endometrial Neoplasms 10Uterine Cervical Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 8Hodgkin Disease 8Brain Neoplasms 8Lymphoma 7Esophageal Neoplasms 7Central Nervous System Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Glioma 6Esophageal Squamous Cell Carcinoma 6Astrocytoma 6Adenocarcinoma of Lung 6Mesothelioma 5

Interventions

tucatinib 1trastuzumab biosimilar HLX02 1ribociclib 1pertuzumab 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Fulvestrant 1Docetaxel 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anatomic Stage II Breast Cancer AJCC v8 × Carboplatin × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡